跳转至内容
Merck
CN

Y0000500

阿卡波糖

European Pharmacopoeia (EP) Reference Standard

别名:

阿卡波糖, 4",6"-二脱氧-4"-([1S]-[1,4,6/5]-4,5,6-三羟基-3-羟甲基-2-环己烯基氨基)-麦芽三糖

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H43NO18
CAS号:
分子量:
645.60
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

Agency

EP Reference Standard

API类

acarbose

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1

InChI key

XUFXOAAUWZOOIT-SXARVLRPSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

应用

阿卡波糖EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

作为可逆性α-葡萄糖苷酶抑制剂的改性四糖。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jun-Peng Yang et al.
Journal of agricultural and food chemistry, 62(31), 7760-7770 (2014-07-16)
Bamboo leaf extract as a food additive has been used for preventing the oxidation of food. In the present study, we investigated the influence of Phyllostachys edulis leaf extract on starch digestion. Orientin, isoorientin, vitexin, and isovitexin were determined as
Sophie Delorme et al.
Current opinion in pharmacology, 5(2), 184-189 (2005-03-23)
The prevalence of glucose intolerance is increasing dramatically worldwide. Both impaired glucose tolerance (IGT) and type 2 diabetes are associated with excess mortality from cardiovascular disease. It is now generally accepted that these cardiovascular complications are related to prevailing hyperglycemia
Matteo Monami et al.
Advances in therapy, 29(9), 736-746 (2012-08-28)
Lipid profile is an important determinant of cardiovascular risk in type 2 diabetes. It is well known that patients with type 2 diabetes are more likely to be dyslipidemic than the general population. Given the observed connection between glucose and
Uwe Zeymer
International journal of cardiology, 107(1), 11-20 (2005-12-13)
Impaired glucose metabolism is associated with an increased risk of cardiovascular events and cardiovascular-associated mortality. Postprandial hyperglycaemia is one of the earliest identifiable indicators of impaired glucose control. It contributes to the progression from impaired glucose tolerance to overt type
Markolf Hanefeld et al.
Cardiovascular drugs and therapy, 22(3), 225-231 (2008-03-01)
Excessive postprandial (pp) glucose excursion in people with IGT and type 2 diabetes is associated with a cascade of proatherogenic events. Acarbose, a potent competitive inhibitor of alpha-glucosidases of the small intestine specifically reduces pp hyperglycemia with an average reduction

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门